Zeng Ao, Xiong Yicheng, Zhang Jing, Yu Huansha, Zhang Lele, Bian Dongliang, Han Lu, Wang Jue, Chen Yan, Shaik Mohammed Saud, Zhang Peng, Dai Jie
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Department of Animal Experiment Center, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Transl Lung Cancer Res. 2024 Jan 31;13(1):16-33. doi: 10.21037/tlcr-23-606. Epub 2024 Jan 29.
Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) exhibited a higher propensity for lymph node metastasis (LNM). This study aimed to investigate risk factors of occult lymph node metastasis (OLNM) and recurrence in resectable ALK-rearranged NSCLC patients.
This retrospective analysis included patients with ALK-rearranged NSCLC receiving lung resections at Shanghai Pulmonary Hospital from June 2016 to August 2021. Logistic regression analysis was used to ascertain predictors of OLNM, and Cox regression analysis to identify risk factors of recurrence.
A total of 603 resectable ALK-rearranged NSCLC patients were included. The mean age was 55 years old. There were 171 patients (28.4%) pathologically confirmed to have LNM, 51.5% of which were occult. Logistic regression analysis identified clinical tumor size and computed tomography (CT) density as independent factors for OLNM. Cox regression analysis showed that pleural invasion and pathological tumor size were independent prognosticators for recurrence in pathologically nodal negative patients. Among pathologically nodal positive patients, adjuvant ALK-tyrosine kinase inhibitors (TKI) showed a similar recurrence-free survival (RFS) to chemotherapy (hazard ratio, 0.454; 95% confidence interval, 0.111-1.864).
Assessing the potential risk of OLNM is required for ALK-rearranged NSCLC patients with large tumors characterized by high CT densities. Patients with large pathological tumor size or pleural infiltration should be closely monitored despite being pathologically nodal negative. Additionally, adjuvant ALK-TKI may present a comparable RFS to chemotherapy in pathologically nodal positive patients.
间变性淋巴瘤激酶(ALK)重排的非小细胞肺癌(NSCLC)表现出更高的淋巴结转移(LNM)倾向。本研究旨在探讨可切除的ALK重排NSCLC患者隐匿性淋巴结转移(OLNM)和复发的危险因素。
这项回顾性分析纳入了2016年6月至2021年8月在上海肺科医院接受肺切除术的ALK重排NSCLC患者。采用逻辑回归分析确定OLNM的预测因素,采用Cox回归分析确定复发的危险因素。
共纳入603例可切除的ALK重排NSCLC患者。平均年龄为55岁。171例(28.4%)患者经病理证实有LNM,其中51.5%为隐匿性。逻辑回归分析确定临床肿瘤大小和计算机断层扫描(CT)密度是OLNM的独立因素。Cox回归分析显示,胸膜侵犯和病理肿瘤大小是病理淋巴结阴性患者复发的独立预后因素。在病理淋巴结阳性患者中,辅助性ALK酪氨酸激酶抑制剂(TKI)的无复发生存期(RFS)与化疗相似(风险比,0.454;95%置信区间,0.111 - 1.864)。
对于具有高CT密度特征的大肿瘤ALK重排NSCLC患者,需要评估OLNM的潜在风险。尽管病理淋巴结阴性,但病理肿瘤大或有胸膜浸润的患者应密切监测。此外,在病理淋巴结阳性患者中,辅助性ALK - TKI可能呈现与化疗相当的RFS。